Literature DB >> 12399408

Neuronal activity is required for the circadian rhythm of vasopressin gene transcription in the suprachiasmatic nucleus in vitro.

Hiroshi Arima1, Shirley B House, Harold Gainer, Greti Aguilera.   

Abstract

Arginine vasopressin (AVP) is synthesized in and secreted by the suprachiasmatic nucleus (SCN) in a circadian pattern. Transcription of the AVP gene in organotypic cultures of rat SCN was studied by using an intronic in situ hybridization. AVP gene transcription in the cultured SCN maintained a daily rhythm with a peak in the daytime. Inhibition of spontaneous activity by the sodium channel blocker, tetrodotoxin (TTX), dramatically decreased AVP heteronuclear RNA levels and suppressed rhythmicity, indicating that ongoing neural activity was required for the AVP gene transcription. In the presence of TTX, the adenylate cyclase stimulator, forskolin, increased AVP transcription in the SCN. In contrast, the protein kinase C activator, phorbol 12-myristate 13-acetate, greatly increased AVP transcription in the absence of TTX, but this effect was blocked by TTX, indicating that the phorbol 12-myristate 13-acetate acted indirectly via synaptic input. Neither protein kinase A nor protein kinase C pathways appear to be involved in the rhythmicity of AVP transcription in the SCN because selective inhibitors of these protein kinases were without effect. In contrast, the MAPK pathway inhibitor, PD98059, profoundly decreased AVP transcription and abolished its daily rhythm. Hence, a functional MAPK signaling pathway appears to be critical for AVP gene expression in the SCN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399408     DOI: 10.1210/en.2002-220393

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Circadian and photic regulation of phosphorylation of ERK1/2 and Elk-1 in the suprachiasmatic nuclei of the Syrian hamster.

Authors:  Andrew N Coogan; Hugh D Piggins
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.

Authors:  Eléonore Beurel; Charles B Nemeroff
Journal:  Curr Top Behav Neurosci       Date:  2014

3.  Functional role of c-Jun-N-terminal kinase in feeding regulation.

Authors:  Elizabeth K Unger; Merisa L Piper; Louise E Olofsson; Allison W Xu
Journal:  Endocrinology       Date:  2009-12-18       Impact factor: 4.736

Review 4.  HPA axis responsiveness to stress: implications for healthy aging.

Authors:  Greti Aguilera
Journal:  Exp Gerontol       Date:  2010-09-09       Impact factor: 4.032

5.  Fos proteins are not prerequisite for osmotic induction of vasopressin transcription in supraoptic nucleus of rats.

Authors:  Hiroshi Arima; Ruben Baler; Greti Aguilera
Journal:  Neurosci Lett       Date:  2010-09-17       Impact factor: 3.046

6.  Organotypic slice culture of the hypothalamic paraventricular nucleus of rat.

Authors:  Eun Seong Cho; So Yeong Lee; Jae Yong Park; Seong Geun Hong; Pan Dong Ryu
Journal:  J Vet Sci       Date:  2007-03       Impact factor: 1.672

7.  Mitogen-activated protein kinase is a functional component of the autonomous circadian system in the suprachiasmatic nucleus.

Authors:  Makoto Akashi; Naoto Hayasaka; Shin Yamazaki; Koichi Node
Journal:  J Neurosci       Date:  2008-04-30       Impact factor: 6.167

8.  Transgenesis and neuroendocrine physiology: a transgenic rat model expressing growth hormone in vasopressin neurones.

Authors:  Sara E Wells; David M Flavell; Gordon W Bisset; Pamela A Houston; Helen Christian; Keith M Fairhall; Iain C A F Robinson
Journal:  J Physiol       Date:  2003-06-17       Impact factor: 5.182

9.  Gene regulation system of vasopressin and corticotropin-releasing hormone.

Authors:  Masanori Yoshida
Journal:  Gene Regul Syst Bio       Date:  2008-03-03

10.  Stress responsiveness of the hypothalamic-pituitary-adrenal axis: age-related features of the vasopressinergic regulation.

Authors:  Nadezhda D Goncharova
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-12       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.